In Good Vein: Introducing the Blood Banking Industry
Welcome back! Today we’re learning about the Blood Banking industry! The Blood Banking and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) industries look like separate worlds, but they are closely intertwined because both handle biological based products derived from the human body. Blood Banking deals with blood and blood components such as red cells, plasma, and platelets [1] . The HCT/P industry deals with human cells, tissues, and cellular and tissue-based products, including, but not limited to, bone, skin, corneas, tendons, birth tissue, and cell-based products. Both industries start with human donations and turn that donation into a medical product. Because of this shared starting point, both industries are built around the same basic mission: impact lives, protect the patient, reduce infection risk, and keep the product traceable from donor to recipient.
What are their similarities?
The biggest similarity is safety control. In both industries, establishments must comprehensively screen donors, test for infectious disease risks, follow written procedures, train staff, maintain controlled storage conditions, keep records, and investigate problems when they happen. The Food and Drug Administration (FDA) regulates both through the biologics framework (FDA’s Center for Biologics Evaluation and Research – CBER [2] ), and many organizations also follow the Association for the Advancement of Blood and Biotherapies (AABB) [3] and the Association for Advancing Tissue and Biologics (AATB) [4] Standards. Both industries depend on quality systems and traceability; if something goes wrong, the product must be traced quickly, and the problem must be contained. With Blood Banking regulations as the predecessor, FDA’s tissue rules were built and are similar around preventing the introduction, transmission, and spread of communicable disease, which is the long-standing safety logic of blood banking.
Where do these industries differ?
Blood banking has a more defined regulatory lane, while HCT/Ps must first be classified. Blood products from the manufacturing and premarket approval process, are almost universally classified as drugs and biologics requiring full premarket review. By contrast, many HCT/Ps fall under Section 361 of the Public Health Service (PHS) Act, if they’re minimally manipulated and used for their original function (homologous use), they do not require premarket approval. Blood products are generally regulated under 21 CFR Part 600, 606, 610, 630, and 640 [5], with licensure requirements also applying where appropriate. HCT/Ps on the other hand, that qualify as “361 HCT/Ps”, mainly follow 21 CFR Part 1271 [6], or if they fall outside that category and become higher risk “351 products”, this can trigger biologics, drug, or device requirements. Blood banking encompasses renewable, fluid components (e.g., red blood cells, platelets, plasma). HCT/Ps encompass solid tissues and cellular structures (e.g., bone allografts, stem cells, reproductive tissue, etc.). Blood products have a shorter shelf life and rely on steady large scale volunteer donation cycles versus many HCT/P tissue grafts that can be processed, sterilized, and banked for months or years.
Historically, blood banking developed formal donor-safety systems earlier and tissue regulation later adopted many of the same ideas. Donor screening, infectious disease testing, quarantine style controls, recordkeeping, deviation investigation, and traceability all became standard expectations in HCT/P regulation. At the same time, both fields continue to respond to emerging disease risks. Blood guidance has emphasized pathogen reduction and bacterial risk control, while new HCT/P guidance has expanded focus on sepsis, Mycobacterium tuberculosis, and updated donor eligibility recommendations.
In general, for blood banking, common establishments include community blood centers, hospital transfusion services, source plasma centers, donor testing and diagnostic laboratories, and biopharmaceutical companies. These operations typically focus on compliance with 21 CFR Part 606 for product-specific blood standards, Part 607 for registration and listing, and Parts 600 and 601 where licensure applies. Many also align operations with the AABB. In the HCT/Ps world, common establishments include tissue acquisition/recovery organizations, tissue banks, and processors of higher-risk cell or tissue products. If the product qualifies as a “361 HCT/P”, the regulatory pathway is 21 CFR Part 1271, if the product does not meet the “361 HCT/P” criteria, the manufacturer may also need to comply with additional drug, device, or biologics rules. This is why classification is so important in HCT/P compliance, the same donated starting material can lead to very different legal obligations depending on how the product is processed and what it’s intended to do.
In everyday terms, blood banking and HCT/Ps belong to the same donation-based safety universe. They share the same core mission, but don’t always follow the same rulebook. Blood banking is usually more standardized versus HCT/Ps, which are more classification driven and the compliance path can vary from relatively narrow tissue rules to full biologics, drug, or device regulation. Thanks for joining our introduction on blood banking!
See you next time!
Have any questions? Reach out to us here!
References
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC2897192/
[2] https://www.fda.gov/vaccines-blood-biologics/blood-blood-products/regulation-blood-supply
[3] https://www.aabb.org/ (AABB, Standards for Blood Banks and Transfusion Services overview)
[4] https://www.aatb.org/ (AATB, Standards for Tissue Banking overview)
[5] https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F
[6] https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271